Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 253 publications

Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomas.

Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomas.

Journal: The Journal of clinical investigation
Published: August 12, 2025

5-hydroxymethylcytosine deposition mediates Polycomb Repressive Complex 2 function in MYCN -amplified neuroblastoma.

5-hydroxymethylcytosine deposition mediates Polycomb Repressive Complex 2 function in MYCN -amplified neuroblastoma.

Journal: bioRxiv : the preprint server for biology
Published: July 17, 2025

Unraveling the Epigenetic Landscape of Mature B Cell Neoplasia: Mechanisms, Biomarkers, and Therapeutic Opportunities.

Unraveling the Epigenetic Landscape of Mature B Cell Neoplasia: Mechanisms, Biomarkers, and Therapeutic Opportunities.

Journal: International journal of molecular sciences
Published: July 06, 2025

Small-Molecule Drugs in Pediatric Neuro-Oncology.

Small-Molecule Drugs in Pediatric Neuro-Oncology.

Journal: Current oncology (Toronto, Ont.)
Published: June 28, 2025

BRCA1-Associated Protein 1 and Enhancer of Zeste Homolog 2: Pathway Interaction and Therapeutic Intervention in Breast Cancer, Mesothelioma, and Lymphoma.

BRCA1-Associated Protein 1 and Enhancer of Zeste Homolog 2: Pathway Interaction and Therapeutic Intervention in Breast Cancer, Mesothelioma, and Lymphoma.

Journal: JCO precision oncology
Published: June 17, 2025

Safety and efficacy of HH2853, a novel EZH1/2 dual inhibitor, in patients with refractory solid tumours or non-Hodgkin lymphomas: a phase I study.

Safety and efficacy of HH2853, a novel EZH1/2 dual inhibitor, in patients with refractory solid tumours or non-Hodgkin lymphomas: a phase I study.

Journal: EClinicalMedicine
Published: May 06, 2025

A Real-World Disproportionality Analysis of FDA Adverse Event Reporting System Events for Tazemetostat.

A Real-World Disproportionality Analysis of FDA Adverse Event Reporting System Events for Tazemetostat.

Journal: Therapeutic innovation & regulatory science
Published: April 29, 2025

Mechanisms and Therapeutic Implications of EZH2 in Nasal Diseases.

Mechanisms and Therapeutic Implications of EZH2 in Nasal Diseases.

Journal: Clinical reviews in allergy & immunology
Published: April 24, 2025

SETD2 and EZH2: Two epigenetic drivers of prostate cancer.

SETD2 and EZH2: Two epigenetic drivers of prostate cancer.

Journal: Journal of Cancer
Published: April 14, 2025

SMARCB1 Deficiency as a Driver of the Hallmarks of Cancer in Rhabdoid Tumours: Novel Insights into Dysregulated Energy Metabolism, Emerging Targets, and Ongoing Clinical Trials.

SMARCB1 Deficiency as a Driver of the Hallmarks of Cancer in Rhabdoid Tumours: Novel Insights into Dysregulated Energy Metabolism, Emerging Targets, and Ongoing Clinical Trials.

Journal: Metabolites
Published: April 04, 2025

Efficacy and safety of tazemetostat, an EZH2 inhibitor, in Chinese patients with relapsed/refractory follicular lymphoma: a multicentre, single-arm, phase 2 study.

Efficacy and safety of tazemetostat, an EZH2 inhibitor, in Chinese patients with relapsed/refractory follicular lymphoma: a multicentre, single-arm, phase 2 study.

Journal: EClinicalMedicine
Published: March 29, 2025

A Systematic Literature Review of the Economic and Healthcare Resource Utilization Burden of Relapsed/Refractory Follicular Lymphoma.

A Systematic Literature Review of the Economic and Healthcare Resource Utilization Burden of Relapsed/Refractory Follicular Lymphoma.

Journal: PharmacoEconomics - open
Published: March 25, 2025
Showing 1-12 of 253

Last Updated: 10/31/2025